- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Collaborators
- Suppliers
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- Research centres
- People
- Alistair Brown
- Anne-Laure Puaux
- Assoc Prof Joanna Groom
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Ethan Goddard-Borger
- Associate Professor Gemma Kelly
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor John Wentworth
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Kelly Rogers
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Melissa Call
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Shalin Naik
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Tracy Putoczki
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Belinda Phipson
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gwo Yaw Ho
- Dr Hamish King
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Jim Whittle
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Nadia Davidson
- Dr Nadia Kershaw
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Sarah Best
- Dr Saskia Freytag
- Dr Shabih Shakeel
- Dr Sheau Wen Lok
- Dr Stephin Vervoort
- Dr Yunshun Chen
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor Daniel Gray
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor James Murphy
- Professor Jane Visvader
- Professor Jeanne Tie
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leanne Robinson
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marnie Blewitt
- Professor Matthew Ritchie
- Professor Melanie Bahlo
- Professor Melissa Davis
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Czabotar
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Sandra Nicholson
- Professor Sant-Rayn Pasricha
- Professor Seth Masters
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Papenfuss
- Professor Wai-Hong Tham
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Clinician-scientist training
- Undergraduate
- Student research projects
- A multi-pronged approach to targeting myeloproliferative neoplasms
- A new paradigm of machine learning-based structural variant detection
- A whole lot of junk or a treasure trove of discovery?
- Advanced imaging interrogation of pathogen induced NETosis
- Analysing the metabolic interactions in brain cancer
- Atopic dermatitis causes and treatments
- Boosting the efficacy of immunotherapy in lung cancer
- Building a cell history recorder using synthetic biology for longitudinal patient monitoring
- Characterisation of malaria parasite proteins exported into infected liver cells
- Deciphering the heterogeneity of the tissue microenvironment by multiplexed 3D imaging
- Defining the mechanisms of thymic involution and regeneration
- Delineating the molecular and cellular origins of liver cancer to identify therapeutic targets
- Developing computational methods for spatial transcriptomics data
- Developing drugs to block malaria transmission
- Developing models for prevention of hereditary ovarian cancer
- Developing statistical frameworks for analysing next generation sequencing data
- Development and mechanism of action of novel antimalarials
- Development of novel RNA sequencing protocols for gene expression analysis
- Discoveries in red blood cell production and function
- Discovering epigenetic silencing mechanisms in female stem cells
- Discovery and targeting of novel regulators of transcription
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Dissecting mechanisms of cytokine signalling
- Doublecortin-like kinases, drug targets in cancer and neurological disorders
- Epigenetic biomarkers of tuberculosis infection
- Epigenetics – genome wide multiplexed single-cell CUT&Tag assay development
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Exploiting the cell death pathway to fight Schistosomiasis
- Finding treatments for chromatin disorders of intellectual disability
- Functional epigenomics in human B cells
- How do nutrition interventions and interruption of malaria infection influence development of immunity in sub-Saharan African children?
- Human lung protective immunity to tuberculosis
- Improving therapy in glioblastoma multiforme by activating complimentary programmed cell death pathways
- Innovating novel diagnostic tools for infectious disease control
- Integrative analysis of single cell RNAseq and ATAC-seq data
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigation of a novel cell death protein
- Malaria: going bananas for sex
- Mapping spatial variation in gene and transcript expression across tissues
- Mechanisms of Wnt secretion and transport
- Multi-modal computational investigation of single-cell communication in metastatic cancer
- Nanoparticle delivery of antibody mRNA into cells to treat liver diseases
- Naturally acquired immune response to malaria parasites
- Organoid-based discovery of new drug combinations for bowel cancer
- Organoid-based precision medicine approaches for oral cancer
- Removal of tissue contaminations from RNA-seq data
- Reversing antimalarial resistance in human malaria parasites
- Role of glycosylation in malaria parasite infection of liver cells, red blood cells and mosquitoes
- Screening for novel genetic causes of primary immunodeficiency
- Single-cell ATAC CRISPR screening – Illuminate chromatin accessibility changes in genome wide CRISPR screens
- Spatial single-cell CRISPR screening – All in one screen: Where? Who? What?
- Statistical analysis of single-cell multi-omics data
- Structural and functional analysis of epigenetic multi-protein complexes in genome regulation
- Structural basing for Wnt acylation
- Structure, dynamics and impact of extra-chromosomal DNA in cancer
- Targeted deletion of disease-causing T cells
- Targeting cell death pathways in tissue Tregs to treat inflammatory diseases
- The cellular and molecular calculation of life and death in lymphocyte regulation
- The role of hypoxia in cell death and inflammation
- The role of ribosylation in co-ordinating cell death and inflammation
- Understanding Plasmodium falciparum invasion of red blood cells
- Understanding cellular-cross talk within a tumour microenvironment
- Understanding the genetics of neutrophil maturation
- Understanding the roles of E3 ubiquitin ligases in health and disease
- Unveiling the heterogeneity of small cell lung cancer
- Using combination immunotherapy to tackle heterogeneous brain tumours
- Using intravital microscopy for immunotherapy against brain tumours
- Using nanobodies to understand malaria invasion and transmission
- Using structural biology to understand programmed cell death
- Validation and application of serological markers of previous exposure to malaria
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Ashley Weir
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jasmine Rou
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Krishneel Prasa
- Lilly Backshell
- Malvika Kharbanda
- Megan Kent
- Naomi Jones
- Pailene Lim
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Sophie Collard
- Wayne Cawthorne
- Wil Lehmann
- Yanxiang Meng
- Zhong Yan Gan
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- Learning Hub
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A generous vision for impactful medical research
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Philanthropy through the power of sisterhood
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- Donors
- WEHI.TV
New way to prevent heart complications in children
17 October 2022
Researchers have identified a new way to treat young children with Kawasaki Disease (KD) to prevent life-threatening coronary artery damage and heart attacks.
The WEHI-led study showed that treatment with drugs called mTOR inhibitors can prevent the formation of coronary artery damage and aneurysms, a much-feared complication of KD.
Importantly, mTOR inhibitors are already known to be safe and effective in other clinical uses, meaning this therapy could potentially be trialled rapidly in the clinic for children with KD.
At a glance
- Kawasaki Disease is the leading cause of acquired heart disease in children
- Existing therapies are effective for most but not all patients with KD, and those who develop coronary artery damage and aneurysms are at risk of heart attack
- New study provides compelling pre-clinical evidence that mTOR inhibitors can prevent progression of coronary artery damage
- mTOR inhibitors are already available and have proven safety and efficacy in other clinical uses
no heart disease (left) and the effect of acute Kawasaki
Disease (right). Credit: WEHI
KD mainly affects children under five years of age and is the most common cause of acquired heart disease in children in developed countries. Up to 300 Australian children are diagnosed with the disease each year.
The specific cause of KD is unknown, but it is generally accepted that infections with common respiratory viruses, including coronavirus, can trigger the disease.
A key clinical feature of KD is inflammation of blood vessels, particularly the coronary arteries that supply blood to the heart.
When severe, this inflammation can cause ‘remodelling’ of the coronary arteries that lead to narrowing and aneurysms in damaged arteries, where the walls weaken and blow out like a balloon.
Risk of heart attack
Severe narrowing and large aneurysms as a result of KD can lead to potentially fatal damage to the heart and predispose patients to heart attacks later in life.
Professor Ian Wicks, Joint Head of Clinical Translation at WEHI, said even children with KD who survive aneurysms may sustain long-term damage to their coronary arteries, requiring treatment including surgery.
“Preventing coronary artery damage is the top priority in KD treatment,” said Professor Wicks.
“Current treatments effectively reduce the risk of developing potentially deadly aneurysms in most children, but we need more options for children whose KD is resistant to these treatments.
“The risk of blood clotting and heart attack in these children makes it very important that we identify therapies that can prevent coronary artery damage.”
Study co-lead author Dr Angus Stock said the new research findings suggested that mTOR inhibitors were capable of both preventing and treating these adverse changes in KD patients who developed coronary artery aneurysms.
“This is particularly exciting as mTOR inhibitors have a proven safety and efficacy profile in related clinical uses, such as preventing arteries from re-narrowing after coronary stenting in adults,” he said.
Cause of coronary damage identified
Credit: WEHI
The WEHI team first investigated the cellular processes that cause KD and showed that remodelling and narrowing of the coronary arteries is driven by overactivity of local connective tissue cells called cardiac fibroblasts.
The researchers were able to identify the source of this abnormal activity as a particular cell-signalling pathway called the mechanistic target of rapamycin (mTOR).
Analysis of the hearts of patients who died as a result of KD confirmed that mTOR signalling was enhanced or ‘up-regulated’ in fibroblasts within inflamed coronary arteries from these children.
“Our research confirmed that mTOR tells fibroblasts in the coronary artery to multiply, causing thickening of the innermost layer of the artery wall,” explained Dr Stock, Senior Research Officer in the Wicks Laboratory at WEHI.
“We then focused on blocking mTOR signalling with rapamycin – the prototype and best-known mTOR inhibitor – as a way of disrupting this proliferation of coronary fibroblasts and hence preventing aneurysms and narrowing of the coronary arteries.”
The study, published in the journal Arthritis & Rheumatology, showed that treatment with rapamycin, also known as sirolimus, limited the growth and activity of fibroblasts in a pre-clinical model of Kawasaki disease.
mTOR inhibitors are currently used in adults to treat and prevent stenosis of coronary arteries and to prevent organ rejection after transplantation.
The drugs can be given orally, giving them a clinical advantage over treatments that must be injected or given intravenously.
“These findings set the scene for clinical trials to assess a currently-used medicine to prevent coronary artery damage and heart disease in treatment-resistant KD,” said Professor Wicks.
Funding support for the research was provided by the NHMRC and WEHI donors Jenny Tatchell and the John T Reid Charitable Trusts.
The authors acknowledge and thank the families of patients with KD and the families of organ donors for allowing the use of their tissue samples in the study.
The study, ‘mTOR inhibition prevents coronary artery remodeling in a murine model of Kawasaki disease’, conducted in collaboration with Dr Sarah Parsons from the Victorian Institute of Forensic Medicine (VIFM), is published in Arthritis & Rheumatology (DOI: 10.1002/art.42340).
WEHI authors: Angus Stock, Damian D’Silva, Jacinta Hansen, Ian Wicks
Media enquiries
M: +61 475 751 811
Super Content:
Want to hear about our latest discoveries? Subscribe to our supporter newsletter, Illuminate.
The Conversation examines the burden of rheumatic heart disease in Australia.